---
schema_version: "secwatch.filing_event.v1"
accession: "0001559053-23-000002"
form_type: "8-K"
ticker: "PRTA"
cik: "0001559053"
company_name: "PROTHENA CORP PUBLIC LTD CO"
filed_at: "2023-02-23T23:59:59+00:00"
generated_at: "2026-06-19T02:36:00.227187+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Prothena reports Q4 net income $6.3M, full year net loss $116.9M; provides 2023 guidance

## Summary
- Q4 2022 revenue $49.9M (incl. $40M Novo Nordisk milestone); full year revenue $53.9M vs $200.6M in 2021.
- Cash, cash equivalents and restricted cash $712.6M at Dec 31, 2022; no debt.
- 2023 guidance: net cash used in operating/investing $213-229M; year-end cash ~$512M.
- PRX012 Phase 1 topline data expected year-end 2023; PRX005 Phase 1 MAD topline also year-end 2023.
- Birtamimab Phase 3 AFFIRM-AL topline data expected 2024; prasinezumab Phase 2b topline 2024.

## SEC filing metadata
- accession: 0001559053-23-000002
- form_type: 8-K
- ticker: PRTA
- cik: 0001559053
- company_name: PROTHENA CORP PUBLIC LTD CO
- filed_at: 2023-02-23T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559053/000155905323000002/0001559053-23-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559053/000155905323000002/prta-20230223.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001559053-23-000002
- JSON: https://secwatch.observer/filing/0001559053-23-000002.json
- Plain text: https://secwatch.observer/filing/0001559053-23-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.